ArticleFrontiers in cardiovascular medicine2025
Role of insulin signaling dysregulation in pulmonary vascular remodeling in rats with monocrotaline-induced pulmonary arterial hypertension.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary arterial hypertension (PAH) is a severe disease marked by the remodeling of arteries due to the abnormal growth of vascular cells, including pulmonary arterial smooth muscle cells (PASMCs). The insulin receptor substrate-1 (IRS-1) plays a crucial role in the insulin signaling pathway; however, its function in PAH is still not fully understood. The objective of this research was to explore the role of the protein kinase C (PKC)/IRS-1/ERK signaling pathway in the progression of PAH and its influence on the proliferation and migration of PASMCs. Methods: To establish the PAH model, low-dose Monocrotaline (MCT) was intraperitoneally administered to male SD rats twice a week. Four weeks following the initial treatment, measurements of mean pulmonary arterial pressure (mPAP) and the right ventricular hypertrophy index (RVHI) were conducted. Additionally, calculations were performed to determine the percentage of wall area (WA%) and wall thickness (WT%). The protein levels of PKC, p-PKC, IRS-1, p-IRS-1 (Ser318), ERK, and p-ERK in lung tissues were assessed. Results: In PAH rats, there was a significant rise in mPAP and RVHI ( Conclusions: The PKC/IRS-1/ERK signaling pathway is implicated in the abnormal proliferation and migration of PASMCs, contributing to pulmonary vascular remodeling in PAH. Targeting this pathway through PKC inhibition or IRS-1 stabilization may offer novel therapeutic strategies for PAH management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.